Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/RNAC/Catalyst
Phase 2Data readout

Descartes-08

Myositis

RNACCartesian Therapeutics
Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset
Descartes-08
Development stage
Phase 2
Event type
Data readout
Indication
Myositis

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Descartes-08 in Myositis. The expected timing is based on the latest available company guidance and may change.

Development notes

11/13/25- File IND by YE 2025. Initiate Ph2 trial in H1 2026. 03/09/26:- FDA accepted IND; Ph2 TRITON myositis trial initiation reiterated for H1 2026. 04/30/26:- Phase 2 TRITON myositis trial of Descartes-08 initiated; first 10 patients to guide pivotal path. 08/06/26:- TRITON Ph2 subset data expected H1 2027 to guide pivotal path.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from RNAC

Related pipeline programs

Phase 3

Descartes-08

Myasthenia gravis

View company pipeline
Phase 1/2

Descartes-08

Juvenile dermatomyositis, Juvenile systemic lupus erythematosus (SLE), Juvenile Myasthenia gravis (MG), Anti-neutrophil cytoplasmic antibody associated vasculitis

View company pipeline

Company

Cartesian Therapeutics

RNAC · NasdaqGM
Industry
Biotechnology
Pipeline assets
8
View RNAC research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy